Invida Group Pte Ltd. has entered into a partnership agreement with Roche for the commercialization and marketing of Roche’s primary care portfolio throughout Korea. Invida’s commercialization of these products and will allow Roche to focus on its specialty care portfolio in Korea. Invida will manage all of the marketing and sales activities for Roche’s primary care products, including Xenical and Roaccutane, as well as products from Roche’s CNS portfolio, including Madopar for the treatment...